Durand-Zaleski I - Search Results

1

A cost analysis of the prevention of end-stage renal disease: immunoglobulin therapy for IgA nephropathy.

Durand-Zaleski I, Bastuji-Garin S, Zaleski S, Weil B, Rostoker G. Durand-Zaleski I, et al. Med Decis Making. 1996 Oct-Dec;16(4):326-34. doi: 10.1177/0272989X9601600403. Med Decis Making. 1996. PMID: 8912294

2

DEALE-ing and discounting: a simple way to compute the accrued costs of preventive strategies.

Durand-Zaleski I, Zaleski S. Durand-Zaleski I, et al. Med Decis Making. 1994 Jan-Mar;14(1):98-103. doi: 10.1177/0272989X9401400112. Med Decis Making. 1994. PMID: 8152363

3

Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin.

Rostoker G, Durand-Zaleski I, Petit-Phar M, Ben Maadi A, Jazaerli N, Radier C, Rahmouni A, Mathieu D, Vasile N, Rosso J, et al. Rostoker G, et al. Nephron. 1995;69(1):20-8. doi: 10.1159/000188355. Nephron. 1995. PMID: 7891793 Clinical Trial.

4

[Evaluation of diagnostic or screening procedures. Validity of tests, sensitivity, specificity, predictive values. Definition and indications for mass screening].

Durand-Zaleski I, Bastuji-Garin S. Durand-Zaleski I, et al. Rev Prat. 2000 May 15;50(10):1155-8. Rev Prat. 2000. PMID: 10905104 French. No abstract available.

5

[Measuring the state of health of the population. Mortality, morbidity, health indicators, incidence, prevalence, attack levels. Risk, risk factors, risk groups, main characteristics of morbidity and mortality in France].

Bastuji-Garin S, Durand-Zaleski I. Bastuji-Garin S, et al. Rev Prat. 1996 May 15;46(10):1281-6. Rev Prat. 1996. PMID: 8763684 French. No abstract available.

6

Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial.

Sobhani I, Itti E, Luciani A, Baumgaertner I, Layese R, André T, Ducreux M, Gornet JM, Goujon G, Aparicio T, Taieb J, Bachet JB, Hemery F, Retbi A, Mons M, Flicoteaux R, Rhein B, Baron S, Cherrak I, Rufat P, Le Corvoisier P, de'Angelis N, Natella PA, Maoulida H, Tournigand C, Durand Zaleski I, Bastuji-Garin S. Sobhani I, et al. Ann Oncol. 2018 Apr 1;29(4):931-937. doi: 10.1093/annonc/mdy031. Ann Oncol. 2018. PMID: 29365058 Free PMC article. Clinical Trial.

7

Pulmonary embolism; lung scanning interpretation: about words.

Bastuji-Garin S, Schaeffer A, Wolkenstein P, Godeau B, Carville C, Durand-Zaleski I, Meignan M. Bastuji-Garin S, et al. Chest. 1998 Dec;114(6):1551-5. doi: 10.1378/chest.114.6.1551. Chest. 1998. PMID: 9872187

8

A tale of two countries: costs and financial incentives for provisional stenting during percutaneous coronary intervention in France and the United States.

Durand-Zaleski I, Dupouy P, Coste Carrié DP, Furber A, Bastuji-Garin S, Steg PG, Dubois-Randé JL, Kern M, Lafont A. Durand-Zaleski I, et al. Eur J Health Econ. 2002;3(4):235-9. doi: 10.1007/s10198-002-0130-9. Eur J Health Econ. 2002. PMID: 15609148 Clinical Trial.

9

[Measuring the state of health of the population. Mortality, morbidity, indicators of health, incidence, prevalence, attack levels. Risk, risk factors, risk groups, principal characteristics of the morbidity and mortality in France].

Durand-Zaleski I, Bastuji-Garin S, Lacronique JF. Durand-Zaleski I, et al. Rev Prat. 1993 May 15;43(10):1321-4. Rev Prat. 1993. PMID: 8235377 French. No abstract available.

10

[Quality of life evaluation: public health aspects].

Schwarzinger M, Bastuji-Garin S, Durand-Zaleski I. Schwarzinger M, et al. Ann Dermatol Venereol. 1999 Feb;126(2):168-75. Ann Dermatol Venereol. 1999. PMID: 10352837 French. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

388 results

Search Page